Primo Nery Lara Jr. MD

Clinical Trials

• Trastuzumab and Docetaxel in Treating Patients Who Have Metastatic Prostate Cancer That Is Refractory to Hormone Therapy Start of enrollment: 2000 Aug 01

  Completed

  Phase 2

• SU5416 and Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer Start of enrollment: 2000 Nov 01

  Completed

  Phase 2

• Chloroquinoxaline Sulfonamide in Treating Patients With Small Cell Lung Cancer Start of enrollment: 2000 Dec 01

  Completed

  Phase 2

• BMS-247550 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy Start of enrollment: 2001 Jun 01

  Completed

  Phase 2

• R115777 in Treating Patients With Advanced Solid Tumors Start of enrollment: 2001 Aug 01

  Completed

  Phase 1

• Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer Start of enrollment: 2002 Oct 01

  Completed

  Phase 3

• BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy Start of enrollment: 2002 May 01

  Completed

  Phase 2

• S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer Start of enrollment: 2002 Nov 01

  Completed

  Phase 3

• S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium Start of enrollment: 2003 Jan 01

  Completed

  Phase 2

• Perifosine in Treating Patients With Recurrent Prostate Cancer Start of enrollment: 2003 Mar 01

  Terminated

  Phase 2

• Tirapazamine Combined With Chemo and RT in Limited-Stage Small Cell Lung Cancer Start of enrollment: 2003 Sep 01

  Completed

  Phase 2

• Bortezomib in Treating Patients With Recurrent or Refractory Extensive-Stage Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy Start of enrollment: 2003 Sep 01

  Completed

  Phase 2

• Gemcitabine, Carboplatin, and Bortezomib in Advanced or Recurrent Non-Small Cell Lung Cancer Start of enrollment: 2004 Jan 01

  Completed

  Phase 2

• S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy Start of enrollment: 2006 Aug 01

  Completed

  Phase 3

• Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer Start of enrollment: 2006 Sep 26

  ACTIVE_NOT_RECRUITING

  PHASE3

• Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer Start of enrollment: 2006 Jul 01

  Completed

  Phase 2

• Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer Start of enrollment: 2007 May 08

  Active, not recruiting

  Phase 3

• Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer Start of enrollment: 2004 Sep 01

  Terminated

  Phase 2

• S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2008 Dec 01

  Completed

  Phase 2

• Sorafenib in Treating Patients With Advanced Malignant Solid Tumors Start of enrollment: 2008 Dec 01

  Completed

  Phase 2

• Gemcitabine and Erlotinib in Treating Patients With Metastatic or Recurrent Pancreatic Cancer Start of enrollment: 2009 Apr 01

  Completed

  Phase 2

• Use of Low Dose Ketoconazole in Prostate Cancer That Does Not Respond to Hormone Therapy and Prior Chemotherapy Start of enrollment: 2009 May 01

  Completed

  Phase 2

• Calcium-41 (41Ca) Chloride Aqueous Solution in Diagnosing Patients With Prostate Cancer and Bone Metastasis Start of enrollment: 2009 Sep 01

  Terminated

  Not Applicable

• Temsirolimus and Pazopanib in Patients With Advanced Solid Tumors Start of enrollment: 2010 Feb 01

  Completed

  Phase 1

• Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer Start of enrollment: 2010 Dec 01

  Completed

  Phase 2

• S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Start of enrollment: 2011 Apr 01

  ACTIVE_NOT_RECRUITING

  PHASE3

• MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy Start of enrollment: 2011 Feb 01

  Completed

  Phase 2

• Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer Start of enrollment: 2011 Sep 06

  Completed

  Phase 1

• S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08

  ACTIVE_NOT_RECRUITING

  PHASE3

• Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer Start of enrollment: 2014 Jan 22

  Active, not recruiting

  Phase 3

• Radiologically Guided Biopsies of mCRPC Start of enrollment: 2013 Feb 22

  Completed

• Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer Start of enrollment: 2015 Sep 01

  Completed

  Phase 1

• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Start of enrollment: 2015 Aug 17

  ACTIVE_NOT_RECRUITING

  PHASE2

• Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer Start of enrollment: 2016 Nov 15

  Completed

  Phase 1, Phase 2

• Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations Start of enrollment: 2017 Aug 24

  ACTIVE_NOT_RECRUITING

  PHASE2

• Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer Start of enrollment: 2017 Jul 19

  ACTIVE_NOT_RECRUITING

  PHASE2

• Join now to see all